Jacobs Solutions Inc. (NYSE:J), known for its strong position in the
bio-tech market, has recently experienced substantial maneuvering among major stakeholders and institutional investors. Entities like
Cetera Investment Advisers and
Mather Group LLC have respectively increased and decreased their holdings. An important strategic shift was announced along with plans for
shares repurchase, followed by an encouraging Q3 report where the company met its EPS and exceeded revenue expectations. This led to RBC and William Blair offering an increased
price target, though Robert W. Baird trimmed its target slightly. Traditional investors like
American International Group and
ProShare Advisors adjust their positions while competitor comparison indicates an underperformance in the market. The company guidance for FY24 earnings indicates positivity alongside a
stock rating upgrade by StockNews.com.
Insider sales evince some hesitancy, while investors five years ago would’ve seen
97% gains. With 87% institutional ownership, company forecasts suggest $1.94/share earnings in Q3 2024. Analysts grant the company a
'Moderate Buy' consensus, indicating a stable future. Finally, the company beat Q3 revenue estimates amid steady demand in the infrastructure business.
Jacobs Solutions Stocks News Analytics from Sun, 12 Nov 2023 08:00:00 GMT to Sun, 11 Aug 2024 18:47:06 GMT -
Rating 3
- Innovation -2
- Information 5
- Rumor -5
